Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit.

Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer.

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

Daiichi Sankyo, an innovative global healthcare company, has established a state-of-the-art research laboratory in San Diego, California, US, dedicated to the development of robotics, automation and ...

A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients. The ...